New Indication: Durvalumab for Limited Stage SCLC


  • Study

    Phase 3, randomized, double-blind, placebo-controlled trial, multicenter
    Limited-stage small-cell lung cancer (LS-SCLC) after chemoradiation
    Durvalumab vs. placebo



  • Efficacy

    Median OS: 55.9 mos vs. 33.4 mos (durvalumab vs. placebo) (HR: 0.73 [0.54-0.98])
    Median PFS: 16.6 mos vs. 9.2 mos (HR: 0.76 [0.59-0.98])
    Among 175 pts with measurable disease: Objective response: 30.3% vs. 32.0%



  • Safety

    Grade ≥3 AEs: Pneumonitis (3.1% vs. 2.6%), Rash (12.1% vs. 0.3%), Diarrhea (9.3% vs. 0.3%)
    Serious AEs: 29.8% vs. 24.2% (durvalumab vs. placebo)
    Discontinuations due to AEs: 16.4% vs. 10.6% (durvalumab vs. placebo)



  • N Engl J Med 2024;391:1313-1327

    Cheng Y,Spigel RD,Cho BC Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

    http://doi.org/10.1056/NEJMoa2404873

    Reviewed by Ulas D. Bayraktar, MD on Dec 6, 2024